GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (OTCPK:MDBIF) » Definitions » YoY EBITDA Growth

TrivarX (TrivarX) YoY EBITDA Growth : -100.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is TrivarX YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TrivarX's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -100.00%.

TrivarX's EBITDA per Share for the six months ended in Dec. 2023 was $-0.00.


TrivarX YoY EBITDA Growth Historical Data

The historical data trend for TrivarX's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX YoY EBITDA Growth Chart

TrivarX Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.45 90.51 77.59 -546.15 88.10

TrivarX Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.14 -942.86 66.67 89.04 -100.00

TrivarX YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TrivarX's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-0.01--0.084)/ | -0.084 |
=88.10 %

TrivarX's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.002--0.001)/ | -0.001 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TrivarX YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of TrivarX's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


TrivarX (TrivarX) Business Description

Traded in Other Exchanges
Address
647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.

TrivarX (TrivarX) Headlines

From GuruFocus

Medibio Submits FDA De Novo Application

By Marketwired Marketwired 07-16-2018

Medibio finalizes acquisition of Vital Conversations

By Marketwired Marketwired 04-12-2018

Medibio Releases Corporate Health Product, ilumen™

By Marketwired Marketwired 10-03-2018

Medibio Named Finalist for Prestigious Optus My Business Award

By Marketwired Marketwired 10-01-2018

Medibio Announces Executive Leadership Changes

By Marketwired Marketwired 09-21-2018

Medibio Receives TGA Approval

By Marketwired Marketwired 06-19-2018

Receipt of $3,146,835 R&D Tax Incentive Refund

By Marketwired Marketwired 10-15-2018

Medibio Provides Market Update

By Marketwired Marketwired 09-10-2018